Literature DB >> 16681753

Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis.

H-C Lai1, M-Y Peng, S Nieh, C-P Yu, C-C Chang, Y-W Lin, C-A Sun, T-Y Chu.   

Abstract

Human papillomavirus (HPV) load was reported to be related to the severity of cervical neoplasia but with controversy. The viral load-disease severity relationship was showed in HPV 16, but no study was made in HPV 58, the second most prevalent HPV in cervical cancer in East Asia. We studied cervical HPV loads in HPV 16- and HPV 58-infected cases of normal, low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), and invasive cervical cancer (CC) by using quantitative polymerase chain reaction (Q-PCR) with type-specific primers in defined cell number. With the exception of HPV 16 infection in normal, viral loads varied greatly in each disease regardless of genotypes. The load of HPV 16 differed significantly among disease severities, with a dramatic increase from normal (1.14 +/- 2.25 copies/cell) to LSIL, HSIL, and CC (1599 +/- 2301, 7489 +/- 24,087 and 1878 +/- 2979 copies/cell, respectively) (P < 0.01). No significant difference was noted among different HPV 58 infections, with loads in normal, LSIL, HSIL, and CC of 503 +/- 641, 7951 +/- 27,557, 353 +/- 744, and 1139 +/- 2895 copies/cell, respectively. In comparison with HPV 16, HPV 58 subclinical infection confers a significant higher load (P < 0.01). Different HPV types behave differentially in the spectrum of cervical carcinogenesis. Unlike HPV 16, the infection load of HPV 58 does not correlate to the clinical severity. The wide variation of HPV loads among different HPV types and among squamous intraepithelial lesions and CC makes the viral load test unrealistic in differentiating different severities of cervical neoplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681753     DOI: 10.1111/j.1525-1438.2006.00390.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study.

Authors:  Long Fu Xi; James P Hughes; Philip E Castle; Zoe R Edelstein; Chunhui Wang; Denise A Galloway; Laura A Koutsky; Nancy B Kiviat; Mark Schiffman
Journal:  J Infect Dis       Date:  2011-03-16       Impact factor: 5.226

2.  Kinetics of DNA load predict HPV 16 viral clearance.

Authors:  M Marks; P E Gravitt; U Utaipat; S B Gupta; K Liaw; E Kim; A Tadesse; C Phongnarisorn; V Wootipoom; P Yuenyao; C Vipupinyo; S Rugpao; S Sriplienchan; D D Celentano
Journal:  J Clin Virol       Date:  2011-03-09       Impact factor: 3.168

3.  Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development.

Authors:  Rachel L Winer; Tiffany G Harris; Long Fu Xi; Kathrin U Jansen; James P Hughes; Qinghua Feng; Carolee Welebob; Jesse Ho; Shu-Kuang Lee; Joseph J Carter; Denise A Galloway; Nancy B Kiviat; Laura A Koutsky
Journal:  J Med Virol       Date:  2009-04       Impact factor: 2.327

4.  Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3.

Authors:  Long Fu Xi; Nancy B Kiviat; Denise A Galloway; Xiao-Hua Zhou; Jesse Ho; Laura A Koutsky
Journal:  J Infect Dis       Date:  2008-08-01       Impact factor: 5.226

5.  Combined SYBR Green real-time polymerase chain reaction and microarray method for the simultaneous determination of human papillomavirus loads and genotypes.

Authors:  Hyun Hee Seo; Young Jun Kim; Mi Seon Jeong; Sung Ran Hong; In Ho Lee; Kyeong A So; Mi-Kyung Kim; Yoo Kyung Lee; Ki Heon Lee; Juree Kim; Sung Jae Kim; Tae Jin Kim
Journal:  Obstet Gynecol Sci       Date:  2016-11-15

6.  Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR.

Authors:  Ian Roberts; Grace Ng; Nicola Foster; Margaret Stanley; Michael T Herdman; Mark R Pett; Andrew Teschendorff; Nicholas Coleman
Journal:  BMC Biotechnol       Date:  2008-07-24       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.